Impact of retroperitoneal lymph node dissection in ovarian cancer - time for paradigm shift?


Journal

Hormone molecular biology and clinical investigation
ISSN: 1868-1891
Titre abrégé: Horm Mol Biol Clin Investig
Pays: Germany
ID NLM: 101538885

Informations de publication

Date de publication:
09 Aug 2019
Historique:
received: 07 05 2019
accepted: 11 07 2019
pubmed: 10 8 2019
medline: 30 9 2020
entrez: 10 8 2019
Statut: epublish

Résumé

Ovarian cancer is the second most common malignant neoplasm of the genital tract. Staging procedures for ovarian cancer include longitudinal laparotomy, hysterectomy, bilateral salpingo-oophorectomy and infragastric omentectomy as well as systematic pelvic and para-aortic lymphadenectomy. In general, the goal of this primary procedure is to achieve the maximum cytoreduction of all abdominal diseases; a residual disease <1 cm defines optimal cytoreduction, however, a maximal effort should be made to remove all gross disease as this offers superior survival outcomes. The role of lymphadenectomy in ovarian cancer has been the focus of gynecological oncologists during recent years. The core issue of the controversy is whether the removal of lymph nodes should be performed only to stage the disease or if the removal itself improves survival. To further comprehend the issue, one must take into account that several studies have shown that systematic lymphadenectomy is associated with a risk of vascular injury, lymph cyst formation, pulmonary embolism and increased post-operative mortality even when performed by surgeons with extensive experience. We present an extensive review of the available literature on the matter, hoping to provide some insight into the true need for such a procedure.

Identifiants

pubmed: 31398143
doi: 10.1515/hmbci-2019-0020
pii: hmbci-2019-0020
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Références

Kim HS, Ju W, Jee BC, Kim YB, Park NH, Song YS, et al. Systematic lymphadenectomy for survival in epithelial ovarian cancer. A meta-analysis. Int J Gynecol Cancer. 2010;20:520–8.
Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. Cancer Biol Med. 2017;14:9–32.
Powless CA, Aletti GD, Bakkum-Gamez JM, Cliby WA. Risk factors for lymph node metastasis in apparent early-stage epithelial ovarian cancer: implications for surgical staging. Gynecol Oncol. 2011;122:536–40.
Meinhold-Heerlein I, Fotopoulou C, Harter P. Statement by the Kommission Ovar of the AGO: The New FIGO and WHO classifications of ovarian, fallopian tube and primary peritoneal cancer. Geburtshilfe Frauenheilkd. 2015;75:1021–7.
Fleming GF, Seidman J, Yemelyanova A. Principles and practice of Gynecologic Oncology, 7th ed. Philadelphia, PA: Wolters Kluwer Health, 2017.
Panici PB, Angioli R. Role of lymphadenectomy in ovarian cancer. Best Pract Res Clin Obstet Gynecol. 2002;16:529–51.
Panici PB, Maggioni A, Hacker N, Landoni F, Ackermann S, Campagnutta E, et al. Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J Nat Cancer Institute. 2005;97:560–6.
Gao J, Yang X, Zhang Y. Systematic lymphadenectomy in the treatment of epithelial ovarian cancer: a meta-analysis of multiple epidemiology studies. Japanese J Clin Oncol. 2015;45:49–60.
Panici PB, Scambia G, Baiocchi G. Anatomical study of paraaortica and pelvic lymph nodes in gynecological malignancies. Obstet Gynecol. 1992;79:498–502.
Bogani G, Tagliabue E, Ditto A, Signorelli M, Martinelli F, Casarin J, et al. Assessing the risk of pelvic and para-aortic nodal involvement in apparent early-stage ovarian cancer: a predictors- and nomogram-based analyses. Gynecol Oncol. 2017;147:61–65.
Kleppe M, Wang T, Van Gorp T, Slangen BF, Kruse AJ, Kruitwagen RF. Lymph node metastasis in stages I and II ovarian cancer: a review. Gynecol Oncol. 2011;123:610–14.
Minig L, Heitz F, Cibula D, Bakkum-Gamez JM, Germanova A, Dowdy SC, et al. Patterns of lymph node metastases in apparent stage I low-grade epithelial ovarian cancer: a multicenter study. Ann Surg Oncol. 2017;24:2720–6.
Lago V, Mining L, Fotopoulou C. Incidence of lymph node metastases in apparent early-stage low-grade epithelial ovarian cancer a comprehensive review. Int J Gynecol Cancer. 2016;26:1407–14.
Iwase H, Takada T, Iitsuka C, Nomura H, Abe A, Taniguchi T, et al. Clinical significance of systematic retroperitoneal lymphadenectomy during interval debulking surgery in advanced ovarian cancer patients. J Gynecol Oncol. 2015;26:303–10.
Harter P, Gnauert K, Hils R, Lehmann TG, Fisseler-Eckhoff A, Traut A, et al. Pattern and clinical predictors of lymph node metastases in epithelial ovarian cancer. Int J Gynecol Cancer. 2007;17:1238–44.
Zhou J, Zhang W, Zhang QG, He ZY, Sun JY, Chen QH, et al. The effect of lymphadenectomy in advanced ovarian cancer according to residual tumor status: a population-based study. Int J Surg. 2018;52:11–15.
Pereira A, Perez-Medina T, Magrina JF, Magtibay PM, Rodriguez-Tapia A, de Leon J, et al. Correlation between the extent of intraperitoneal disease and nodal metastasis in node-positive ovarian cancer patients. EJSO. 2014;40:917–24.
Mikami M. Role of lymphadenectomy for ovarian cancer. J Gynecol Oncol. 2014;25:279–81.
Kleppe M, van der Aa MA, Von Gorp T, Slangen BF, Kruitwagen RF. The impact of lymph node dissection and adjuvant chemotherapy on survival: a nationwide cohort study of patients with clinical early-stage ovarian cancer. Eur J Cancer. 2016;66:83–90.
du Bois A, Reuss A, Harter P, Pujade-Lauraine E, Ray-Coquard I, Pfisterer J. Potential role of lymphadenectomy in advanced ovarian cancer: a combined exploratory analysis of three prospectively randomized phase III multicenter trials. J Clin Oncol. 2010;28:1733–9.
Fagotti A, De Iaco P, Fanfani F, Vizzielli G, Perelli F, Pozzati F, et al. Systematic pelvic and aortic lymphadenectomy in advanced ovarian cancer patients at the time of interval debulking surgery: a double-institution case-control study. Ann Surg Oncol. 2012;19:3522–7.
Harter P, Sehouli J, Lorusso D, Reuss A, Vergote I, Marth C, et al. LION: lymphadenectomy in ovarian neoplasms – a prospective randomized AGO study group led gynecologic cancer intergroup trial. J Clin Oncol. 2017;35:5500.

Auteurs

Sara Tato-Varela (S)

Department of Gynecology and Obstetrics, Donau-Isar Klinikum Hospital, Perlasberger Straße 41, 94469Deggendorf, Lower Bavaria, Germany.

Walther Kuhn (W)

Department of Gynecology and Obstetrics, Donau-Isar Klinikum Hospital, Deggendorf, Lower Bavaria, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH